Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A topping-out ceremony has taken place at the Old Road Campus to mark the completion of the main structure of the University’s new Global Health Building

Constructors outside the building with yellow vest

A topping-out ceremony has taken place at the Old Road Campus to mark the completion of the main structure of the University’s new Global Health Building – a major new teaching and research facility and a key part of the University’s efforts to improve health and save lives all over the world.

Professor Susanna Dunachie, Director of the Centre for Global Health Research in the Nuffield Department of Medicine, Richard Haynes, Professor of Renal Medicine and Clinical Trials, in Oxford Population Health, and Trevor Payne, the University’s Director of Estates, marked the milestone by adding the last concrete to the top of the building’s structure. Also present for the topping-out was Steve Vaux, Operations Director at main contractor Morgan Sindall. Work will now continue towards an expected completion date in summer 2026.

Read the full piece on the University Estates Services website

Similar stories

University of Oxford and Serum Institute of India agree licence to advance the next-generation multi-stage malaria vaccine candidate component

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.